From: Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis
Mean value
95% CI
Incremental cost, 20 years horizon
−30,682 €
−14,550 € to −49,401 €
Incremental cost, 70 years horizon
−36,743 €
−19,072 € to −57,365 €